2 completed, 1 active not recruiting, 1 recruiting. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Sutezolid: new trials by email Literature Review of Sutezolid trials Research Report on Sutezolid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis Isoniazid, Rifampicin, Pyrazinamide - Pulmonary Tuberculosis | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 315 | 2025-03-11 | 2026-10-19 |
| A Pan-TB Regimen Targeting Host and Microbe Sutezolid, N-acetyl cysteine, Pretomanid - Tuberculosis | Phase 2 / Phase 3 | Active not recruiting | The Aurum Institute NPC | 352 | 2023-07-28 | 2025-05-28 |
| PanACEA Sutezolid Dose-finding and Combination Evaluation Sutezolid, Bedaquiline, Delamanid, Moxifloxacin, Midazolam oral solution - Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis | Phase 2 | Completed | Michael Hoelscher | 75 | 2021-05-06 | 2023-05-01 |
| Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Sutezolid, Placebo - Tuberculosis, Tuberculosis, Pulmonary | Phase 1 | Completed | Global Alliance for TB Drug Development | 32 | 2017-09-26 | 2018-02-08 |
Tuberculosis (3) · Tuberculosis, Pulmonary (3) · Gram-Positive Bacterial Infections (1)
Global Alliance for TB Drug Development (1) · Michael Hoelscher (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · The Aurum Institute NPC (1)
South Africa (3) · Tanzania (2) · Botswana (1) · Brazil (1) · Haiti (1) · India (1) · Kenya (1) · Malawi (1) · Mexico (1) · Mozambique (1) · Peru (1) · Philippines (1) · Thailand (1) · Uganda (1) · United States (1)
Kelly Dooley, MD, PhD (1) · Michael Hoelscher, Prof. (1) · Paul Bruinenberg, MD (1) · Professor Robert Wallis, MD (1) · Radojka Savic, PharmD, PhD (1)